A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Sponsor: |
NIH |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAS2351 |
U.S. Govt. ID: |
NCT02923778 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to evaluate the effectiveness of preoperative radiation therapy used in combination with the immunostimulatory agent talimogene laherparepvec (T-VEC) to improve outcomes for patients with resectable soft tissue sarcomas, including soft tissue sarcoma (liposarcoma (excluding myxoid liposarcoma), leiomyosarcoma and undifferentiated pleomorphic sarcoma), arising in the trunk or chest wall.
This study is closed
Investigator
Matthew Ingham, MD
Are you 18 years or older? |
Yes |
No |
Do you have a soft tissue sarcoma? |
Yes |
No |
Do you agree to use contraception during study treatment and for 4 months after the end of treatment? |
Yes |
No |